Today: 9 June 2026
Sandisk stock price jumps 5% as SNDK steadies after a wild week — what traders watch next
6 February 2026
1 min read

Sandisk stock price jumps 5% as SNDK steadies after a wild week — what traders watch next

New York, Feb 6, 2026, 16:05 EST — After-hours

Sandisk Corporation closed Friday at $606.91, up 5.3%, after bouncing around between $568.30 and $623.28. The stock managed to recoup losses from a volatile run. Western Digital surged 8.7%, Seagate picked up 6.3%, and Micron finished 3.2% higher—gains running through storage and memory stocks.

The rebound’s got traders buzzing, with SNDK now seen as a leveraged bet on AI data center demand—and options action is surging. TipRanks pointed out the unusually intense options flow and higher implied volatility, signaling traders bracing for bigger moves. Raymond James just bumped its rating to “Outperform,” too. TipRanks

Sandisk’s share price has been anything but steady lately. According to MarketBeat, the stock has seen intraday moves of roughly 20% in recent sessions, following a surge that began in January.

Investors are still digesting Sandisk’s late-January guidance bombshell. The company put out fiscal third-quarter revenue targets of $4.4 billion to $4.8 billion, and adjusted earnings in the $12 to $14 per share range—both numbers topping consensus. Sandisk also renewed a major supply pact with Kioxia, locking it in through 2034. Morgan Stanley’s team called earnings “above the long-term trend,” and said that could stick around for another year or more, as long as AI appetite holds up. Reuters

Sandisk, headquartered in Milpitas, California, reported a 61% jump in second-quarter revenue, hitting $3.03 billion. Adjusted earnings landed at $6.20 per share. CEO David Goeckeler said in the statement that “accelerating enterprise SSD deployments” and a stronger product mix drove the gains. Sandisk

Sandisk only recently popped up as its own ticker in the U.S., debuting as a standalone after splitting from Western Digital back in February 2025.

Traders are keeping an eye out for fresh supply, as Form 144 filings landed with the U.S. Securities and Exchange Commission this week, indicating planned share sales. The form lets affiliates flag their intention to unload restricted or control stock.

Finviz picked up a Zacks note suggesting Sandisk’s forecast signals a tightening in the NAND space—a key type of flash memory for solid-state drives. The commentary flagged Sandisk’s margin gains and bumped-up consensus estimates. Zacks also pointed out that over the past three months, Sandisk shares have outpaced Western Digital, Micron, and Seagate.

This trade is packed, and sentiment can turn quickly in memory cycles. Investors.com pointed out that while there’s been plenty of buzz dubbing “memory” the “new gold,” some voices are cautioning about short-term pullbacks after such rapid run-ups. Investors

U.S. markets reopen Monday, and traders are eyeing options flows and fresh selling disclosures. Next up on the earnings calendar: an April 29 release, per Seeking Alpha.

Stock Market Today

  • Cotton Futures Hold Steady Amid Mixed Trading and Market Moves
    June 9, 2026, 9:23 AM EDT. Cotton futures showed mixed performance on Monday with 5 to 15 point gains in most contracts, except July which fell 25 points by midday. The US dollar index declined to 99.94, while crude oil prices rose by 79 cents. Weekly Commodity Futures Trading Commission (CFTC) data revealed speculative funds reduced their net long positions in cotton by 1,798 contracts to 52,402 as of June 2. The Seam reported sales of 1,311 bales at 74.00 cents per pound, while the Cotlook A Index dropped 135 points to 86.15 cents on Friday. ICE certified cotton stocks increased by 11,219 bales to 261,648 on June 5. Key futures: July cotton at 73.5 cents (down 25), December 77.59 (up 11), March 78.85 (up 5). This reflects cautious market sentiment amid variable data.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Confluent stock edges higher as IBM deal vote nears after fresh merger filing
Previous Story

Confluent stock edges higher as IBM deal vote nears after fresh merger filing

Oracle stock rebounds after a bruising week — what traders are watching next for ORCL
Next Story

Oracle stock rebounds after a bruising week — what traders are watching next for ORCL

Go toTop